Unknown

Dataset Information

0

Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Patients.


ABSTRACT: Background:Erlotinib is presently the first line treatment for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) active mutation. An increasing number of evidences show that the treatment efficacy and toxicities are considerably heterogeneous among individuals. Hence, it is necessary to find biological predictors for further individualized treatment of erlotinib in NSCLC patients. Methods:Our present study enrolled 87 cases of NSCLC patients who had been administrated erlotinib with a fixed dose (150 mg/d). Eleven polymorphisms in seven genes of drug-metabolizing enzymes and transporters were genotyped and the steady state trough concentrations were also determined. Results:There were significant variances in the steady-state erlotinib trough plasma concentrations, ranging from 315.6 ng/ml to 4479.83 ng/ml. Erlotinib steady state trough concentration was remarkably lower in current smoking patients. The steady state trough concentration of GG in rs1048943 of CYP1A1 was significantly higher than that of AA allele carriers. The polymorphism of CYP1A2 was significantly associated with the severity of skin rash, and the development of diarrhea was associated with SNPs in ABCB1 and CYP3A5. We also observed that GG allele in CYP1A1 was accompanied with a longer PFS in our study. Conclusion:A large variability of erlotinib steady state trough concentration was found among Chinese Han population. SNPs in CYP1A1 appeared to influence the steady state trough concentration of erlotinib. Correlation between CYP1A2 polymorphisms and severity of skin rash was observed, together with the correlation between the development of diarrhea and SNPs in ABCB1 and CYP3A5.

SUBMITTER: Liao D 

PROVIDER: S-EPMC7225310 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Patients.

Liao Dehua D   Liu Zhigang Z   Zhang Yongchang Y   Liu Ni N   Yao Dunwu D   Cao Lizhi L   Chen Yun Y   Fu Yilan Y   Yang Nong N   Xiang Daxiong D  

Frontiers in pharmacology 20200508


<h4>Background</h4>Erlotinib is presently the first line treatment for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) active mutation. An increasing number of evidences show that the treatment efficacy and toxicities are considerably heterogeneous among individuals. Hence, it is necessary to find biological predictors for further individualized treatment of erlotinib in NSCLC patients.<h4>Methods</h4>Our present study enrolled 87 cases of NSCLC patients who had b  ...[more]

Similar Datasets

| S-EPMC5323433 | biostudies-literature
| S-EPMC10376485 | biostudies-literature
| S-EPMC5551680 | biostudies-literature
| S-EPMC3507503 | biostudies-literature
| S-EPMC5992792 | biostudies-literature
| S-EPMC7138722 | biostudies-literature
| S-EPMC5709143 | biostudies-literature
| S-EPMC8593121 | biostudies-literature
| S-EPMC3634068 | biostudies-literature